Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive drug discovery services encompass the entire research and development process, ranging from target validation and hit identification to lead generation, lead optimization, and PCC nomination. These services are adept across diverse therapeutic modalities, such as small molecules, antibodies, peptides, ADCs, and PROTACs. The company's intelligent automation solutions specifically utilize artificial intelligence and automation to facilitate the accelerated discovery and research of novel drugs and materials. Established in 2015 and based in Shenzhen, China, the firm was formerly known as QuantumPharm Inc. before officially changing its name to XtalPi Holdings Limited in December 2024.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of 2228.HK is 12.0 and suggests 66.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i